Modafinil Articles
Mylan settles Provigil litigation with Teva
10 June 2012
Teva debuts generic of Provigil, Avapro and Avalide; Ranbaxy Crestor copy OKed in Canada
1 April 2012
Opportunities for Pharma in narcolepsy
20 February 2012
EMEA says modafinil can only be used for treatment of narcolepsy; all other indications to be removed
23 July 2010
US FTC Chairman, Congressmen call for legislation to end “pay-for-delay” deals to stop generics
14 January 2010
FDA eyes orlistat for potential liver problems, Chantix under scrutiny for skin reaction
5 June 2009
Cephalon swings back to profit in 3rd qtr
1 December 2008
One-in-five in the USA could have Ritalin for non-medical use
20 October 2008
Cephalon exceeds guidance for 2nd qtr
11 August 2008
FDA sues Cephalon for generic blocking
25 February 2008
Cephalon's 1st-qtr income soars to $75M
14 May 2007
Japan stock market week to April 9, 2007
16 April 2007
Cephalon's Nuvigil gets tentative OK from FDA
9 April 2007
Stock Commentary - New York week to March 5, 2007
12 March 2007
Stock Commentary - New York week to Feb 19, 2007
26 February 2007
Stock Commentary - New York week to Dec 11, 2006
18 December 2006
Cephalon updates on final Nuvigil labeling
11 December 2006
Cephalon's 3rd-qtr 2006 sales increases 56%
13 November 2006
Biotech stocks in holding pattern for August, says Burrill report
18 September 2006
Cephalon swings to profit in 2nd-qtr 2006
14 August 2006
Japan stock market week to June 19, 2006
26 June 2006
Cephalon/Takeda to promote Provigil in US
19 June 2006
UK science chief advocates "smart drugs"
12 June 2006
Cephalon's Sparlon safe and effective for ADHD
29 May 2006
Japan stock market week to April 10, 2006
17 April 2006
Stock Commentary - New York week to March 27, 2006
3 April 2006
Stock Commentary - New York week to Mar 20, 2006
27 March 2006
Cephalon's full-year 2005 loss deepens 130%
27 February 2006
Cephalon and Teva settle Provigil patent dispute
19 December 2005
Cephalon's Sparlon improves ADHD symptoms in children
12 December 2005
Stock Commentary - New York week to Sept 5
12 September 2005
McNeil to co-promote modafinil for ADHD with Cephalon
5 September 2005
Cephalon sees 19% sales jump in 2nd qtr
15 August 2005
Provagil "improves wakefulness"
15 August 2005
Stock Commentary - New York
6 June 2005
Cephalon files NDA with FDA for Nuvigil
11 April 2005
Cephalon post record results for 2004
28 February 2005
Generic approvals for Mylan and Teva
21 February 2005
Cephalon's 3rd-qtr loss grows on charges
15 November 2004
In August, biotech emerges from doldrums, but uncertainty persists: Burrill review
13 September 2004
Cephalon's 1st-qtr sales up 49% to $215M
10 May 2004
Provigil cleared for new use in UK
19 April 2004
Cephalon's Provigil shows promise in schizophrenia
22 March 2004
FDA OKs expanded use of Provigil
2 February 2004
Cephalon on track to expand Provigil label
27 October 2003
Cephalon product sales leap 147%
18 August 2003
Stock Commentary - New York
14 July 2003
Cephalon misses targets in first quarter
19 May 2003
Cephalon files patent suits over generic Provigil
7 April 2003
Pfizer takes on India's Ranbaxy over Lipitor
3 March 2003
FDA filings in brief
6 January 2003
Cephalon turnover rockets in 2nd quarter
12 August 2002
Cephalon's sales grow 134%; losses down
20 May 2002
Stock Commentary - New York
11 February 2002
Cephalon gets more rights to Gabitril
14 January 2002
Cephalon completes Lafon acquisition
7 January 2002
Cephalon sets up sales JV
7 January 2002
Cephalon completes Lafon acquisition
31 December 2002
Cephalon sets up sales JV
21 December 2001
Stock Commentary - New York
11 October 2001
Promising results for Cephalon's Provigil
14 June 2001
Novartis ties up with Cephalon in UK marketing pact
7 December 2000
Stock Commentary New York
3 August 2000
No ADHD benefit with Cephalon's Provigil
1 August 2000
Cephalon to acquire Anesta in $444M deal
18 July 2000
Orphan Medical looks to future with Xyrem
27 January 2000
Stock Commentary New York
11 October 1999
Stock Commentary New York
15 July 1999
Stock Commentary New York
24 June 1999
Cephalon to comarket Gabitril in USA
15 June 1999
Cephalon starts Provigil trials
29 April 1999
Stock Commentary New York
14 April 1999
Cephalon launches Provigil in USA
18 February 1999
Stock Commentary New York
18 February 1999
FDA approves another generic Zantac
4 February 1999
Stock Commentary New York
7 January 1999
FDA approves Provigil for narcolepsy
29 December 1998
Myotrophin Dossier Withdrawn In EU
17 September 1998
Marketing Deal For Cephalon Drugs
30 June 1998
Cephalon Appoints Japanese Licensee
15 June 1998
Ireland Approves Cephalon's Provigil
21 May 1998
Cephalon's Provigil Launched In UK
5 March 1998
Cephalon Boosted By Provigil News
15 January 1998
Cephalon's Provigil "Approvable"
6 January 1998
Provigil Cleared In UK
23 October 1997
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
